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efﬁcacy proﬁle. Persistence at 6 months is recommended to maxi-
mise chances of sustained remission and to avoid relapse; inter-
estingly these results show that persistence is also associated with
decreased health care costs. Efforts should be made to promote
persistence on antidepressant treatment.
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OBJECTIVE: Two-month head-to-head clinical trials of escitalo-
pram and venlafaxine demonstrated similar efﬁcacy and better
tolerability for escitalopram. As routine practice may differ from
controlled trial, policy makers wonder how clinical trial ﬁndings
translate into real life outcomes in community practice. This
work compares early treatment discontinuation (ETD) rates at 1
and 2 months and its economic consequences at 6 months, for
patients with depression treated with venlafaxine and escitalo-
pram. METHODS: Using US denominator-based claims data-
base PharMetrics (includes data from 86 managed care health
plans covering 45 million patients), we included adult patients
diagnosed with depression who started venlafaxine or escitalo-
pram between January 1, and December 31, 2004. We compared
ETD at 1 and 2 months using Cox proportional hazard models
and health care costs at 6 months, using log-linear regression.
Propensity scoring was used to account for channelling by indi-
cation. RESULTS: A total of 13,227 patients started escitalo-
pram; 5,922 patients started venlafaxine. ETD at 2 months was
47% for venlafaxine, 45% for escitalopram. At 1 month, ven-
lafaxine patients had a 50% greater risk of ETD than escitalo-
pram patients (Hazard Ratio = 0.493 [95%CI 0.432–0.564]);
this difference decreased at 2 months (Hazard Ratio = 0.955
[95%CI 0.912–0.999]). Six-month health care costs were higher
with venlafaxine (+USD626, p < 0,01). Patients continuing treat-
ment at 2 months had 36% chance of still being on treatment
at 6 months. Patients (all treatments) with ETD at 2 months
incurred more costs over 6 months (+USD350) compared to
patients continuing treatments. CONCLUSION: Early treatment
discontinuation rate was higher with venlafaxine than escitalo-
pram, possibly due to intolerance to venlafaxine. Absence of
ETD was associated with long term persistence and lower total
treatment costs.
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OBJECTIVE: Patients with bipolar disorder are often poorly
medication adherent, resulting in deteriorating symptomology,
higher admission rates, and diminished quality of life. Many
factors are strongly associated with adherence, including ﬁnan-
cial burdens and multiple psychosocial barriers. However, analy-
ses typically consider these barriers independently rather than
conjointly from the patient’s perspective. Such approaches
neglect the complex interplay of risk factors, many of which are
amenable to health policy or clinical interventions. This study
evaluates the differential and cumulative impact of nine barriers
upon medication adherence. METHODS: We recruited 435
patients from the Continuous Improvement for Veterans in
Care—Mood Disorders study (FY04–06). Surveys collected
information on multiple adherence barriers: medication copay-
ments, foregoing treatment due to cost, binge drinking, access
difﬁculty, social support problems, poor therapeutic alliance, and
low medication insight. Multivariable logistic regression
modeled adherence as a function of perceived adherence barriers,
controlling for demographics, homelessness, and affective symp-
tomology. RESULTS: Nearly half of the respondents reported
adherence difﬁculty. Patients experienced an average of 2.8 bar-
riers, with 41% perceiving at least 3. Minority veterans reported
poorer adherence than white patients (56% versus 40%, p =
.01), while claiming more overall barriers, particularly ﬁnancial
burden, binge drinking, and difﬁculty obtaining psychiatric care
when needed. Multivariable models indicated the total number
of barriers was signiﬁcantly associated with poor adherence
(OR = 1.24 per barrier). The most signiﬁcant were low medica-
tion insight, binge drinking, and problems accessing care (ORs of
2.41, 1.95 and 1.73, respectively). CONCLUSION: Veterans
with bipolar disorder experience multiple barriers to medication
adherence, a scenario possibly exacerbated by recent copayment
increases. Certain psychosocial and ﬁnancial obstacles proved
especially pernicious in connection to worse adherence. Recog-
nizing multiple barriers can assist developing tailored clinical
interventions to improve poor adherence by reducing psychoso-
cial risk factors. The interaction with health beneﬁt polices
potentially contributes to burdens faced by patients already expe-
riencing adherence problems.
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OBJECTIVE: The objectives of this study are to describe and
deﬁne a new adherence measure, the Daily Possession Ratio
(DPR), and to contrast that measure with two variants of
the Medication Possession Ratio (MPR, truncated MPR).
METHODS: This study was a retrospective analysis of the North
Carolina Medicaid administrative claims data from July 1999 to
June 2000. Data for non-HMO, non-hospitalized, non-pregnant
schizophrenia patients (ICD-9-CM = 295.**) with at least one
antipsychotic were aggregated to the person-quarter level. The
daily possession ratio was deﬁned as the number of days one or
more antipsychotics was available divided by the total days in the
quarter. Adherence rates were also estimated for subjects that
switched medications or had therapeutic duplication in the
quarter. RESULTS: The ﬁnal sample consisted of 25,200 person-
quarters from 7,069 individuals. For person quarters with single
antipsychotic use, adherence to antipsychotics as a class was:
DPR = 0.607; truncated MPR = 0.640; MPR = 0.695 (p <
0.0001). For person quarters with therapeutic duplication, the
following adherence measures were observed: DPR = 0.669;
truncated MPR = 0.774; MPR = 1.238 (p < 0.0001). CONCLU-
SION: The DPR provides a more conservative estimate of adher-
ence than the MPR across all type of users, however the
differences between the two methods are more substantial for
persons switching therapy and prescribed therapeutic duplica-
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